Clinical Trial Update: GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease [NA]

View source ↗

Summary

A clinical trial is evaluating a GLP-1 receptor agonist for effects on alcohol consumption, metabolism, and liver parameters in patients with obesity and fatty …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Nonalcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• GLP-1 receptor agonist

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Adiposity, Fatty Liver | NA | Status: NOT_YET_RECRUITING